Ceftaroline fosamil for the treatment of staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

Infectious Diseases in Clinical Practice

Volumn 23, Issue 1, 2015, Pages 39-43

  Vazquez, Jose A ^a   Maggiore, Christy R ^b   Cole, Phillip ^c   Smith, Alexander ^c   Jandourek, Alena ^c   Friedland, H David ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Gulf Coast Cancer Treatment Center   (United States)

^c Cerexa Inc   (United States)

Author keywords

ABSSSI; Bacteremia; CABP; CAPTURE; Ceftaroline fosamil; Staphylococcus aureus

Indexed keywords

CEFTAROLINE FOSAMIL;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITAL PATIENT; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; REVIEW; STAPHYLOCOCCAL BACTEREMIA; TREATMENT DURATION;

EID: 84920889474     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0000000000000191     Document Type: Review

References (31)

1. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis. 2009;48: S260-S270.
2. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584-602.
3. Mongardon N, Max A, Bouglé A, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16:R155.
4. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis. 2008;198:336-343.
5. Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:273-279.
6. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008;62: 1413-1421.
7. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-2402.
8. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923-929.
9. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190-196.
10. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
11. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390-398.
12. Finks J, Wells E, Dyke TL, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009;15:943-945.
13. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30:603-610.
14. Cui L, Tominaga E, Neoh HM, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50: 1079-1082.
15. Pate AJ, Terribilini RG, Ghobadi F, et al. Antibiotics for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: the challenge of outpatient therapy. Am J Emerg Med. 2014;32:135-138.
16. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42(suppl 1):S51-S57.
17. Silverman JA, Mortin LI, VanPraagh ADG, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152.
18. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42:e108-e110.
19. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55:4154-4160.
20. Farrell DJ, Castanheira M, Mendes RE, et al. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis. 2012;55(suppl 3):S206-S214.
21. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582-586.
22. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65:713-716.
23. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol. 2007;10: 428-435.
24. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(suppl 3): S173-S180.
25. International Conference on Harmonisation. E6 Good Clinical Practice Guidance. Rockville, MD: Drug Information Branch (HFD-210), Center for Drug Evaluation and Research; 1976.
26. Khosrovaneh A, Sharma M, Khatib R. Favorable prognosis of Staphylococcus aureus bacteremia originating from soft tissues: a prospective study of fifty cases. Scand J Infect Dis. 2005;37:6-10
27. Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267-1270.
28. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013, 19:42-49.
29. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
30. Dreyer NA, Tunis SR, Berger M, et al. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29:1818-1825.
31. Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User's Guide. Rockville, MD: Agency for Healthcare Research and Quality; 2010.